FRAGIN GARY S 4

4 · ZIOPHARM ONCOLOGY INC · Filed Apr 1, 2010

Form 4

Period: 2010-03-31

Director

Transactions

Award
Stock Option (right to buy)
2010-03-31+15,000→ 15,000 total
Exercise: $5.09From: 2011-03-31Exp: 2020-03-31→ Common Stock, $.001 par value (15,000 underlying)
Award
Common Stock, $.001 par value
2010-03-31+15,000→ 67,500 total

Holdings

Stock Option (right to buy)
Exercise: $2.85Exp: 2019-12-31→ Common Stock, $.001 par value (7,500 underlying)
7,500
Stock Option (right to buy)
Exercise: $4.85Exp: 2017-06-18→ Common Stock (15,000 underlying)
15,000
Director Stock Option (right to buy)
Exercise: $5.01From: 2006-04-26Exp: 2016-04-26→ Common Stock (15,000 underlying)
15,000
Stock Option (right to buy)
Exercise: $2.73Exp: 2017-12-12→ Common Stock (20,000 underlying)
20,000
Director Stock Option (right to buy)
Exercise: $4.31From: 2006-12-22Exp: 2014-12-22→ Common Stock, $.001 par value (15,029 underlying)
15,029

Footnotes (6)

[F1]Grant of restricted stock; restrictions lapse on the anniversary of the date of grant.
[F2]In addition to the current grant, includes a prior grant of restricted stock with restrictions that will lapse as to 3,750 shares on each of December 31, 2010 and December 31, 2011.
[F3]5,000 shares vest on each of 6/18/08, 6/18/09 and 6/18/10.
[F4]6,667 shares vest on each of 12/12/08 and 12/12/09; 6,666 shares vest on 12/12/10.
[F5]5,000 shares vest on each of 12/31/2009, 6/30/2010 and 12/31/2010.
[F6]3,750 shares vest on each of 12/31/2010 and 12/31/2011.

Documents

1 file